

ASSIGNMENT

For valuable consideration, we,

Full Name of Assignor	State of Incorporation	Business Address
Shiratori Pharmaceuticals Co., Ltd.	Japan	26F WBG Marive east 2-6-1 Nakase, Mihama-ku, Chiba-shi, Chiba 261-7090 JAPAN

hereby assign to

Full Name of Assignee	State of Incorporation	Business Address
Censa Pharmaceuticals Inc.	United States of America	65 William Street, Suite #200, Wellesley, MA 02481

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more applications for United States Patent signed by us, identified as:

Title of Application	Filing Date	Serial Number
PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERIN	May 30, 2018	62/678,025
PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERIN	September 4, 2018	62/726,612
PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERIN	March 22, 2019	62/822,336

and we authorize and request the attorneys appointed in said application to hereafter complete this assignment by inserting above the filing date and serial number of said application when known; this assignment includes said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.

白鳥 隆夫
Signature

May 29th 2019
Date

Representative Name: Satoshi Shiratori

Representative Title: CEO

Shiratori Pharmaceuticals Co., Ltd.

Witness:

Signature

Date

Printed Name



Signature

July 2nd 2009
Date

Representative Name: JONATHAN REIS

Representative Title: CEO

Censa Pharmaceuticals Inc.

Witness:

Signature

Date

Printed name